Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SWTX | US
-0.19
-0.58%
Healthcare
Biotechnology
30/06/2024
04/10/2024
32.64
32.46
33.10
32.05
SpringWorks Therapeutics Inc. acquires develops and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition it develops BGB-3245 an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford Connecticut.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Weakness based on declining price with high volume
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
29.9%1 month
39.2%3 months
46.5%6 months
47.0%-
294.12
4.31
0.01
0.01
-7.90
23.45
-
-318.71M
2.42B
2.42B
-
-75.20
-
-
-59.73
18.72
22.33
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.04
Range1M
10.42
Range3M
13.27
Rel. volume
1.24
Price X volume
37.55M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
Verona Pharma plc | VRNA | Biotechnology | 32.01 | 2.60B | 11.49% | n/a | 129.87% |
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 42.99 | 2.46B | -1.15% | n/a | 0.51% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -7.90 | 0.76 | Cheaper |
Ent. to Revenue | 23.45 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 4.31 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 46.54 | 74.67 | Lower Risk |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 2.42B | 3.73B | Emerging |